De Novo Software

Executive Summary

De Novo Software is a US-based provider of scientific intelligence platforms for life sciences research, with its flagship product FCS Express leading the flow cytometry data analysis market. Founded in 2000 and headquartered in Los Angeles, the company offers a suite of AI-powered tools spanning bioinformatics, proteomics, electronic lab notebooks, and clinical trial design. By automating workflows and enabling advanced data management, De Novo serves academic, pharmaceutical, and clinical diagnostic laboratories. The company's long-standing presence and deep integration in the cytometry ecosystem position it for growth as AI adoption accelerates in drug delivery and diagnostics. With a focus on enhancing analytical capabilities and regulatory compliance, De Novo is poised to expand its footprint in precision medicine and clinical applications.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) clearance for FCS Express in clinical diagnostics40% success
• Q2 2026Launch of AI-driven proteomics analysis module70% success
• Q3 2026Strategic partnership with top-10 pharma for clinical trial data platform30% success